Compare Eli Lilly And Co (LLY) vs Philip Morris International Inc. (PM) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with a bullish technical signal and strong analyst consensus. Recent financials show robust revenue growth to $40.65B in 2025 and net income of $11.35B, though a Q4 2025 earnings miss and a recent $500M impairment charge highlight near-term pressures. The stock's P/E of 27.17 and P/S of 7.25 reflect premium valuation, supported by a 68% buy rating from analysts and a $194.00 consensus price target.

Outlook remains positive with steady cash flow and dividend payments, but risks include regulatory challenges from rising illicit cigarette trade in Europe and cost pressures. The stock offers stability through high margins and brand strength, yet investors should weigh valuation against earnings volatility and macroeconomic headwinds.